<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - HYDROXYZINE HYDROCHLORIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>HYDROXYZINE HYDROCHLORIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pruritus</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25 mg daily, dose to be taken at night; increased if necessary to 25 mg 3&#8211;4 times a day.</li>
              <li class="dose child"><strong>For children 1&#8211;5 years</strong><br/>
                Initially 5&#8211;15 mg once daily, dose to be taken at night, increased if necessary to 50 mg daily in 3&#8211;4 divided doses.</li>
              <li class="dose child"><strong>For children 6&#8211;11 years</strong><br/>
                Initially 15&#8211;25 mg once daily, dose to be taken at night, increased if necessary to 50&#8211;100 mg daily in 3&#8211;4 divided doses.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 25 mg once daily, dose to be taken at night, increased if necessary to 100 mg daily in 3&#8211;4 divided doses.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Most manufacturers of antihistamines advise avoiding their use during pregnancy; toxicity in <i>animal</i> studies with higher doses.</p><p>Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce daily dose by one-third.</p>
            </section>
            <section class="generalInformation">
              <p>Avoid in severe liver disease&#8212;increased risk of coma.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce daily dose by half.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Avoid in <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref> (some antihistamines are thought to be safe)</li>
            <li><strong>neonates:</strong> neonate (due to significant antimuscarinic activity) in neonates</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>rare:</strong> Anaphylaxis, angioedema, angle-closure glaucoma, arrhythmias, blood disorders, bronchospasm, confusion, convulsions, depression, dizziness, extrapyramidal effects, hypersensitivity reactions, hypotension, liver dysfunction, palpitation, photosensitivity reactions, rashes, sleep disturbances, tremor,
              </p>
              <p>
                <strong>notKnown:</strong> Antimuscarinic effects, blurred vision, drowsiness, dry mouth, gastro-intestinal disturbances, headache, psychomotor impairment, urinary retention,
              </p>
        
        
            <section class="advice">
              <h3 class="specificity">In adults</h3>
              <p>Elderly patients are more susceptible to side-effects.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">In children</h3>
              <p>Children are more susceptible to side-effects.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">In adults</h3>
              <p>Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">In children</h3>
              <p>Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely in children, especially with high doses. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <h3 class="specificity">In adults</h3>
                <p class="title">Hydroxyzine: risk of QT-interval prolongation and Torsade de Pointes (April 2015)</p>
              <p>Following concerns of heart rhythm abnormalities, the safety and efficacy of hydroxyzine has been reviewed by the European Medicines Agency. The review concludes that hydroxyzine is associated with a small risk of QT-interval prolongation and Torsade de Pointes; these events are most likely to occur in patients who have risk factors for QT prolongation, e.g. concomitant use of drugs that prolong the QT interval, cardiovascular disease, family history of sudden cardiac death, significant electrolyte imbalance (low plasma-potassium or plasma-magnesium concentrations), or significant bradycardia.</p><p>To minimise the risk of such adverse effects, the following dose restrictions have been made and new cautions and contra-indications added:</p><ul>
            <li>Hydroxyzine is contra-indicated in patients with prolonged QT- interval or who have risk factors for QT-interval prolongation;</li>
            <li>Avoid use in the elderly due to increased susceptibility to the side-effects of hydroxyzine;</li>
            <li>Consider the risks of QT-interval prolongation and Torsade de Pointes before prescribing to patients taking drugs that lower heart rate or plasma-potassium concentration;</li>
            <li>In adults, the maximum daily dose is 100&#8239;mg;</li>
            <li>In the elderly, the maximum daily dose is 50&#8239;mg (if use of hydroxyzine cannot be avoided);</li>
            <li>The lowest effective dose for the shortest period of time should be prescribed.</li>
            </ul>
            </section>
            <section class="importantSafetyInformation">
              <h3 class="specificity">In children</h3>
                <p class="title">Hydroxyzine: risk of QT-interval prolongation and Torsade de Pointes (April 2015)</p>
              <p>Following concerns of heart rhythm abnormalities, the safety and efficacy of hydroxyzine has been reviewed by the European Medicines Agency. The review concludes that hydroxyzine is associated with a small risk of QT-interval prolongation and Torsade de Pointes; these events are most likely to occur in patients who have risk factors for QT prolongation, e.g. concomitant use of drugs that prolong the QT interval, cardiovascular disease, family history of sudden cardiac death, significant electrolyte imbalance (low plasma-potassium or plasma-magnesium concentrations), or significant bradycardia.</p><p>To minimise the risk of such adverse effects, the following dose restrictions have been made and new cautions and contra-indications added:</p><ul>
            <li>Hydroxyzine is contra-indicated in patients with prolonged QT- interval or who have risk factors for QT-interval prolongation;</li>
            <li>Consider the risks of QT-interval prolongation and Torsade de Pointes before prescribing to patients taking drugs that lower heart rate or plasma-potassium concentration;</li>
            <li>In children with body-weight up to 40&#8239;kg, the maximum daily dose is 2&#8239;mg/kg;</li>
            <li>The lowest effective dose for the shortest period of time should be prescribed.</li>
            </ul>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Epilepsy
          </li>
          <li>
              <strong>:</strong>
            prostatic hypertrophy in adults
          </li>
          <li>
            pyloroduodenal obstruction
          </li>
          <li>
            susceptibility to angle-closure glaucoma
          </li>
          <li>
            susceptibility to QT interval prolongation
          </li>
          <li>
            urinary retention
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>
            <i>Ucerax <tm tmtype="reg"/>
            </i> syrup not licensed for use in children under 1 year.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of HYDROXYZINE HYDROCHLORIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,
            oral suspension,

            <div id="PHP75864"><a href="../medicinalForm/PHP75864.html" data-target="#PHP75864" data-action="load">Tablet</a></div>
            <div id="PHP75879"><a href="../medicinalForm/PHP75879.html" data-target="#PHP75879" data-action="load">Oral solution</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
